Technical Analysis for TTPH - Tetraphase Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.29 -0.87% -0.02
TTPH closed up 0.87 percent on Wednesday, February 19, 2020, on 3.85 times normal volume.
Earnings due: Mar 12
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical TTPH trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -0.87%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.87%
MACD Bullish Signal Line Cross Bullish -0.87%
Pocket Pivot Bullish Swing Setup -0.87%
Volume Surge Other -0.87%
Wide Bands Range Expansion -0.87%
Pocket Pivot Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections through its chemistry technology. Its principal products include eravacycline, an intravenous and oral antibiotic that use as a empiric monotherapy has completed the Phase II clinical trials for the treatment of multi-drug resistant Gram-negative infections; and eravacycline oral formulation that is in Phase I clinical trials to treat complicated urinary tract infections in intravenous-to-oral step-down therapy. The company's products that are under development comprise TP-834; and TP-271 that is in preclinical trials for the treatment of respiratory diseases caused by bacterial biothreat pathogens, as well as engages in the development of Pseudomonas/Gram-negative program. Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is based in Watertown, Massachusetts.
Medicine Chemistry Pharmacology Antibiotics Pyrrolidines Respiratory Diseases Multiple Drug Resistance Pseudomonas Basilea Pharmaceutica Carbapenem Eravacycline

Is TTPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 29.0
52 Week Low 1.99
Average Volume 231,010
200-Day Moving Average 6.62
50-Day Moving Average 2.51
20-Day Moving Average 2.40
10-Day Moving Average 2.25
Average True Range 0.22
ADX 19.6
+DI 22.65
-DI 19.51
Chandelier Exit (Long, 3 ATRs ) 3.21
Chandelier Exit (Short, 3 ATRs ) 2.72
Upper Bollinger Band 3.10
Lower Bollinger Band 1.70
Percent B (%b) 0.43
BandWidth 58.17
MACD Line -0.11
MACD Signal Line -0.12
MACD Histogram 0.0017
Fundamentals Value
Market Cap 117.93 Million
Num Shares 51.1 Million
EPS -2.82
Price-to-Earnings (P/E) Ratio -0.82
Price-to-Sales 58.89
Price-to-Book 2.16
PEG Ratio -0.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.63
Resistance 3 (R3) 2.63 2.52 2.57
Resistance 2 (R2) 2.52 2.44 2.52 2.55
Resistance 1 (R1) 2.42 2.39 2.37 2.42 2.54
Pivot Point 2.31 2.31 2.29 2.31 2.31
Support 1 (S1) 2.21 2.23 2.16 2.21 2.08
Support 2 (S2) 2.10 2.18 2.10 2.07
Support 3 (S3) 2.00 2.10 2.05
Support 4 (S4) 2.00